口服HIV-1衣壳抑制剂VH-499的概念验证试验:抗病毒效果、安全性与耐受性
CINNAMON试验是一项随机、双盲、安慰剂对照的2a期概念验证研究,评估口服VH-499单药治疗未接受过抗逆转录病毒治疗的HIV-1感染者。结果支持VH-499作为长效完整方案组成部分的进一步开发。
要点
- VH-499单药治疗10天使所有剂量组病毒载量下降,最高剂量组平均最大降幅为-2.2 log10。
- 95%的VH-499组受试者未出现新发基因型耐药相关突变。
- 不良事件多为轻中度,无严重不良事件或导致退出的事件。
核心结论
- VH-499单药治疗显示出高效抗病毒活性,耐受性良好,安全性特征有利。
- 结果支持将VH-499作为完整长效方案的一部分进一步开发用于HIV-1治疗。
研究设计与样本
- 随机、双盲、安慰剂对照的2a期概念验证试验(CINNAMON)。
- 10天单药治疗期:第1天和第6天口服VH-499 25、100或250 mg或安慰剂;第11天起开始本地标准抗逆转录病毒治疗。
- 主要终点为至第11天病毒载量相对基线的最大变化。
主要发现
- 所有VH-499剂量组至第11天病毒载量均下降,平均(SD)最大降幅:25 mg组-1.8(0.5),100 mg组-1.8(0.5),250 mg组-2.2(0.4)。
- VH-499暴露量增加与病毒载量下降幅度增大相关。
- 95%(19/20)的受试者未出现新发基因型耐药相关突变。
- 不良事件严重程度为轻度或中度,未报告严重不良事件或导致退出的事件。
临床怎么用
- VH-499作为长效抗逆转录病毒药物的候选,需在完整长效方案中进一步评估。
- 当前数据支持在未接受过治疗的人群中继续开展后续临床研究。
局限性
- 样本量小(VH-499组20人,安慰剂组3人)。
- 单药治疗仅10天,长期安全性和耐药性数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Innovative HIV-1 therapies, especially those with infrequent dosing, are a promising approach to advance progress toward the UNAIDS goal of ending HIV-1 transmission. VH4011499 (VH-499) is a new capsid inhibitor in development as a long-acting antiretroviral agent for HIV-1 treatment. We present the antiviral effect, pharmacokinetics, safety, and tolerability of oral VH-499 from a proof-of-concept phase 2a trial in people with HIV-1. METHODS: The randomized, double-blind, placebo-controlled CINNAMON trial evaluated oral VH-499 monotherapy in adults naive to antiretroviral therapy (ART) with viremia. During a 10-day monotherapy period, participants received VH-499 25, 100, or 250 mg or placebo on Days 1 and 6. After monotherapy, participants initiated locally sourced standard-of-care ART starting on Day 11. The primary endpoint was maximum change from baseline in viral load through Day 11. Secondary endpoints included exposure-response relationship, safety, and tolerability. RESULTS: Twenty-three participants were enrolled (VH-499, n=20; placebo, n=3). Viral load decreased through Day 11 for all VH-499 dose groups (mean [SD] maximum decline: 25 mg, -1.8 [0.5]; 100 mg, -1.8 [0.5]; 250 mg, -2.2 [0.4]). Increasing VH-499 exposures were associated with greater viral load declines. Ninety-five percent (19/20) of participants had no emergent genotypic resistance-associated mutations. Adverse events (AEs) were mild or moderate in severity, and no serious AEs or AEs leading to withdrawal were reported. CONCLUSIONS: VH-499 monotherapy demonstrated highly potent antiviral activity, was well tolerated, and had a favorable safety profile. These results support further development of VH-499 as part of a complete long-acting regimen for HIV-1 treatment (ClinicalTrials.gov, NCT06039579).
引用
- Griesel R, Nuñez SA, Cordova E, et al. Antiviral Effect, Safety, and Tolerability of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor: Proof-of-Concept Trial. Clin Infect Dis. 2026. PMID: 42525562. doi:10.1093/cid/ciag452
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。